Physician profile
Robert C Igwe
NPI 1871674192
$101,934.56
in general payments reported to CMS, 2019-2025
61 companies · $3,401 in 2025
The $3,401 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $19K · 2021: $21K · 2022: $16K · 2023: $2,856 · 2024: $4,748 · 2025: $3,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,418 · Consulting Fee: $1,575 · Education: $11.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,418.42 |
| Consulting Fee | $1,575.00 |
| Education | $11.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $37,433.66 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $27,688.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $14,747.06 | 2019 | |
| Novo Nordisk INC | $8,829.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $2,430.06 | 2019-2025 | Freestyle Libre Pro, Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $1,193.94 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $949.64 | 2019-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $816.71 | 2020-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $775.40 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Mannkind Corporation | $741.60 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $558.91 | 2020-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $508.83 | 2019-2024 | |
| Radius Health, INC. | $399.70 | 2020-2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $353.89 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $327.53 | 2021-2025 | Minimed 780g |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $252.88 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $222.74 | 2020-2023 | Tepezza |
| Alvogen INC | $205.13 | 2022-2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $202.49 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $192.12 | 2020-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $187.30 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $178.77 | 2024-2025 | |
| Sequel Med Tech, LLC | $162.25 | 2025 | Twiist |
| Genzyme Corporation | $157.69 | 2024 | |
| Recordati_rare_diseases_inc. | $154.78 | 2022-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $152.41 | 2019-2025 | Strensiq |
| Abbvie INC. | $150.66 | 2021-2023 | |
| Lifescan, INC. | $149.24 | 2019-2023 | |
| Becton, Dickinson and Company | $131.99 | 2020-2022 | |
| Ibsa Pharma INC. | $122.30 | 2020-2024 | Tirosint, Licart, Licart |
| Madrigal Pharmaceuticals | $113.06 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $107.15 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $90.24 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $85.08 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $80.65 | 2021-2022 | |
| Medtronic Minimed, INC. | $75.48 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $70.94 | 2021-2022 | |
| Esperion Therapeutics, INC. | $65.87 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $65.60 | 2020-2022 | |
| Amphastar Pharmaceuticals, INC. | $59.40 | 2024-2025 | |
| Tolmar, INC. | $59.36 | 2024 | |
| Antares Pharma, INC. | $56.46 | 2020-2023 | Xyosted, Tlando, Nocdurna |
| Clarus Therapeutics INC. | $55.54 | 2021 | |
| Embecta Corp. | $55.24 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Averitas Pharma INC. | $49.34 | 2023-2025 | Qutenza |
| Amryt Pharma Holdings Ltd | $47.23 | 2022-2023 | Mycapssa |
| Halozyme INC | $46.36 | 2023 | |
| Pfizer INC. | $45.70 | 2019-2024 | |
| Cequr Corporation | $45.11 | 2021-2024 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $41.68 | 2025 | Tlando |
| Chiesi USA, INC. | $39.06 | 2025 | Juxtapid, Mycapssa |
| Glaxosmithkline, LLC. | $32.14 | 2025 | Shingrix |
| Eusa Pharma (US) LLC | $29.85 | 2022 | |
| Acella Pharmaceuticals, LLC | $27.93 | 2024-2025 | NP Thyroid 60 |
| Beta Bionics, INC. | $19.37 | 2023-2024 | Ilet Bionic Pancreas |
| Zealand Pharma US, INC. | $17.67 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.56 | 2025 | Azmiro |
| Acerus Pharmaceuticals Corporation | $16.42 | 2020 | |
| Shire North American Group INC | $15.86 | 2019 | |
| Theracosbio, LLC | $15.07 | 2024 | Brenzavvy |
| Grt US Holding, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Igwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.